Risk/Benefit Ratio of New Immunotherapy Strategies

A panel expert discussion

The increase in knowledge about the way the immune system functions is leading to exciting new therapeutic possibilities for cancer patients. A panel of experts met during the ESMO Symposium on Immuno-Oncology (15-16 November 2013, Geneva, Switzerland) to discuss about risk/benefit of:

  • Vaccines
  • Checkpoint inhibitors
  • Adoptive T cell transfer.

Moderator:

  • Solange Peters

Panel experts:

  • Scott Antonia
  • George Coukos
  • Pierre-Yves Dietrich
  • Winald Gerritsen
  • Carl June
  • Ignacio Melero
  • Olivier Michielin

Introduction:

Solange Peters opened the panel giving a summary of the risk and toxicities from novel immunotherapy strategies. The introduction was followed by panel discussion on expected treatment benefits with an aim to provide conclusion on risk/benefit ratio for each option.

Read the panel discussion   |  View the webcast